10-Q: NeoGenomics Q1 2026 Financial Results

NeoGenomics reports an 11.1% revenue increase to $186.7 million for Q1 2026, driven by higher test volumes and strategic initiatives.

Summary

• Net revenue for Q1 2026 was $186.7 million, an 11.1% increase from $168.0 million in Q1 2025.
• Net loss narrowed to $17.1 million ($0.13 per share) compared to a net loss of $25.9 million ($0.20 per share) in the prior year period.
• Gross profit increased to $80.9 million from $73.2 million, though gross margin slightly decreased to 43.3% from 43.6%.
• Operating expenses decreased to $99.1 million from $101.1 million, primarily due to lower general and administrative costs.
• Adjusted EBITDA improved to $9.0 million from $7.1 million in Q1 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a stable, improving quarter where the company successfully narrowed losses and grew revenue, though regulatory and legal overhangs persist.

Positives

• Revenue growth of 11.1% year-over-year.
• Significant reduction in net loss from $25.9 million to $17.1 million.
• Operating expenses decreased by $2.0 million, reflecting improved cost management.
• Adjusted EBITDA increased by $1.9 million, indicating improved operational efficiency.
• Successful dismissal of the Goldenberg shareholder class action lawsuit with prejudice.

Negatives

• Continued net loss of $17.1 million for the quarter.
• Gross profit margin experienced a slight contraction of 0.3% year-over-year.
• Interest income declined significantly by 65.8% due to lower cash balances and interest rates.
• Cash used in operating activities remains negative at $8.1 million.

Risks

• Ongoing regulatory investigation by the OIG regarding consulting and service agreements.
• Potential for future legislative or regulatory actions reintroducing FDA oversight of Laboratory Developed Tests (LDTs).
• Exposure to foreign currency exchange rate fluctuations in the U.K. operations.
• Uncertainty regarding the impact of tariffs and trade policy on supply chain costs.
• Potential for additional legal costs or penalties related to ongoing shareholder derivative actions.

Future Outlook

The company expects to continue its focus on sustainable growth through targeted innovation in therapy selection and Molecular Residual Disease (MRD) testing, while maintaining operational efficiency and expanding its community oncology market presence. Capital expenditures for 2026 are forecasted between $30.0 million and $35.0 million.

Management Comments

• Management remains committed to sustainable growth and transforming cancer care through precision oncology.
• The company is focused on driving operational efficiency through automation and process improvements.
• Management believes the current cash position is sufficient to fund operations for at least the next 12 months.

Industry Context

StockSavvy.ai notes that NeoGenomics continues to navigate a complex regulatory environment for LDTs while competing in a consolidating oncology diagnostics market. The company's shift toward higher-value NGS and MRD testing aligns with broader industry trends favoring precision medicine and personalized therapy selection.

Comparison to Industry Standards

• Revenue growth of 11.1% is competitive with peers in the specialized diagnostics space.
• The company's focus on community oncology channels is a standard strategic differentiator among major reference labs like LabCorp and Quest Diagnostics.
• The gross margin of 43.3% is consistent with high-complexity molecular diagnostic providers.

Corporate Governance

Legal Proceedings

• Goldenberg v. NeoGenomics, Inc. (Shareholder class action dismissed with prejudice, currently under appeal).
• Puskarich v. VanOort, et al. (Shareholder derivative action).
• Wong v. VanOort, et al. (Shareholder derivative action).
• Mellema v. VanOort, et al. (Shareholder derivative action).

Stakeholder Impact

• Shareholders: Potential impact from ongoing legal appeals and regulatory investigations.
• Employees: Continued focus on culture and cross-functional collaboration.
• Customers: Benefit from improved turnaround times and expanded testing menu.

Next Steps

• Continue execution of the 2026 strategic focus areas.
• Monitor the appeal of the Goldenberg Matter.
• Continue interactions with the OIG regarding the ongoing regulatory matter.
• Execute planned capital expenditures of $30-$35 million for 2026.

Key Dates

Recommendation

While the company shows improved operational performance and revenue growth, the ongoing OIG investigation and legal appeals create sufficient uncertainty to warrant a hold rating until these risks are resolved.

Keywords

oncology diagnostics, molecular testing, NGS, clinical laboratory, precision medicine, biomarker testing, NeoGenomics